
Claims

1. A compound represented by formula Ia:



(Ia)

wherein:

R^1 is NH_2;

R^2 is H;

R^{13} is phenyl, optionally substituted with 1, 2 or 3 R^{22};

R^{15} is methyl;

R^{16} is 2-pentyl;

each R^{22} is independently selected from halo, C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, phenyl, hydroxyC_1-C_6alkyl, C_3-C_6cycloalkyl, C_1-C_6alkylcarbonyl, C_3-C_6cycloalkylcarbonyl, carboxyC_1-C_6alkyl, hydroxy, amino, CN, and NO_2, or any two R^{22} groups attached to adjacent ring carbon atoms can combine to form -O-$(CR^{23}R^{23'})_{1-6}$-O-;

R^{23} and $R^{23'}$ are independently H or C_1-C_3alkyl;

or a pharmaceutically acceptable salt and/or solvate thereof.

2. A compound according to claim 1 wherein R^{13} is substituted with one or two R^{22}.


3. A compound according to claim 1, wherein R^{13} is unsubstituted phenyl.

4. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.


5. A pharmaceutical combination comprising a therapeutically effective amount of compound according to claim 1, further comprising one or more additional therapeutic agent(s) selected from the group consisting of chemotherapeutical agent, multi-drug resistance reversing agent and biological response modifier.

6. The pharmaceutical combination according to claim 5, wherein the further therapeutic agent is a chemotherapeutical agent.

7. The compound of claim 1, that is



8. The compound of claim 1, that is



9. The compound of claim 1 that is

